What question did this study set out to answer?

To explore the clinical outcomes of TCF3::HLF-positive pediatric BCP-ALL, particularly in the absence of metabolic complications.

July 12, 2026Annals of HematologyOpen Access

Favorable outcome in TCF3::HLF-positive pediatric B-cell acute lymphoblastic leukemia without classic metabolic complications: A case report

View Full Paper

Ask AI

Bookmark

Authors

Case report demonstrates complete remission in TCF3::HLF-positive BCP-ALL, suggesting favorable outcomes without classic complications.

To explore the clinical outcomes of TCF3::HLF-positive pediatric BCP-ALL, particularly in the absence of metabolic complications.
Cytogenetic analysis of the BCP-ALL patient revealed a high hyperdiploid karyotype and duplication of 1q.
Treatment with a high-risk COG protocol including prednisone, vincristine, daunorubicin, and PEG-asparaginase.
Myeloablative allogeneic hematopoietic stem cell transplantation was performed from a matched related donor.
Achieved complete remission with a day-8 blast count of < 1000/µL and MRD < 0.01%.
Patient remains in complete remission over 2 years post-transplantation.
Absence of classic metabolic complications observed, indicating a potential subgroup with better chemotherapy response.

Hadipour et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark